BioNTech SE (BNTX) Gains from Investment Securities (2018 - 2025)
BioNTech SE (BNTX) reported Gains from Investment Securities of -$931234.8 for Q4 2025, down 771.46% on a YoY basis from $138688.7 in Q4 2024, and up 38.73% sequentially from -$1.5 million in Q3 2025.
BioNTech SE (BNTX) Gains from Investment Securities (2018 - 2025) Analysis & Trends
BioNTech SE (BNTX) has 8 years of Gains from Investment Securities data on file, last reported at -$931234.8 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 771.46% year-over-year to -$931234.8; the trailing twelve-month figure through Dec 2025 stood at -$2.9 million (down 2605.1% YoY), and the FY2025 full-year result was -$2.8 million, down 781.07% from the prior year.
- Gains from Investment Securities grew to -$931234.8 in Q4 2025, from -$1.5 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $211.5 million in Q2 2021 to a low of -$1.5 million in Q3 2025.
- A 5-year average of $12.1 million and a median of $155273.7 in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities surged 29630710.57% in 2021 and tumbled 771.46% in 2025, its largest moves.
- Tracing BNTX's Gains from Investment Securities over 5 years: stood at $4.8 million in 2021, then sank by 95.75% to $204049.5 in 2022, then gained by 5.46% to $215188.0 in 2023, then tumbled by 149.66% to -$106859.5 in 2024, then sank by 771.46% to -$931234.8 in 2025.
- Business Quant data shows BNTX's Gains from Investment Securities at -$931234.8 in Q4 2025, -$1.5 million in Q3 2025, and -$339587.9 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | BioNTech SE | 21.56 Bn | 21.56 Bn | 668.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -931,234.81 |
| Dec 31, 2025 | -931,234.81 |
| Sep 30, 2025 | -1.52 Mn |
| Sep 30, 2025 | -1.52 Mn |
| Jun 30, 2025 | -339,587.91 |
| Jun 30, 2025 | -339,587.91 |
| Mar 31, 2025 | -105,188.44 |
| Mar 31, 2025 | -105,188.44 |
| Dec 31, 2024 | -106,859.54 |
| Dec 31, 2024 | -106,859.54 |
| Jun 30, 2024 | -215,377.52 |
| Jun 30, 2024 | -215,377.52 |
| Dec 31, 2023 | 215,187.98 |
| Dec 31, 2023 | 215,187.98 |
| Sep 30, 2023 | 3.59 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Jun 30, 2023 | 108,892.44 |
| Jun 30, 2023 | 108,892.44 |
| Mar 31, 2023 | 214,668.36 |
| Mar 31, 2023 | 214,668.36 |